MPR Weekly Dose MPR 119 — FDA Panel Votes on Novavax; MMR Vaccination; Dupixent Approval Expanded; Investigative COVID-19 Treatments
The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments.
10 Jun 202215min
MPR Weekly Dose 118 — Ukoniq Approval Withdrawn; Rescue Inhaler to Be Reviewed; Dupilumab Priority Review; Kymriah Update; Novel Postpartum Depression Tx Shows Promise
Ukoniq, a treatment just approved last year, has been withdrawn; We rundown a host of drug pipeline news in asthma, dermatology and oncology; and there's positive results for a novel postpartum depres...
3 Jun 202211min
MPR Weekly Dose 117 — Guidance on Paxlovid Tx; Dupixent Approval; Plaque Psoriasis Cream Approved; COVID-19 Vaccine Response in Under 5s; CDC Monkeypox Alert
The latest guidance for Paxlovid treatment following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; Update on the efficacy of a COVID-19 vaccine in th...
27 Mai 202212min
MPR Weekly Dose 116 — First-in-Class T2D Treatment; FDA Decline Fluvoxamine; Booster Doses for Children; COVID-19, Influenza, and RSV Test; Wearable Furosemide Delivery System
The FDA decide to decline COVID-19 treatment; Booster doses authorized for children; A direct to consumer test to detect COVID-19, influenza, and RSV; And a wearable furosemide delivery system accepte...
20 Mai 202212min
MPR Weekly Dose 115 — Janus Kinase Inhibitor Approved for COVID-19; Varenicline Supply; Janssen Vaccine Limits Set; Test Safety Alert; Potential Hemodialysis Chemical Exposure
Treatment approved for hospitalized COVID-19 patients; Update on Varenicline supply; Limits have been set for the Janssen COVID-19 vaccine; Safety alert issued for a COVID-19 test; And certain hemodia...
12 Mai 202211min
MPR Weekly Dose 114 - USPSTF Aspirin Recommendations; COVID-19 treatment expansion; Accupril Recall; Counterfeit HIV Meds; White House Plan to Tackle Overdose Epidemic
This week: USPSTF recommendations on aspirin use to prevent cardiovascular disease; Veklury indication expanded; Accupril Lots recalled; Legal action on counterfeit HIV medication; And the White House...
29 Apr 202213min
MPR Weekly Dose 113 - Sabizabulin Trial Stopped; Booster Request for Peds; Diversity in Clinical Trials; Myopericarditis Risks Compared for Vaccines; Approval Effect on the Unvaccinated
This week: the halting of the sabizabulin trial in COVID-19; Emergency Use Authorization to be requested for booster dose in 5 to 11 year olds; Diversity in Clinical Trials; Myopericarditis risk compa...
15 Apr 202213min
MPR Weekly Dose 112 - Second COVID-19 Booster Dose Authorized; Sotrovimab Use Limited; Oral COVID-19 Tx; PreHevbrio Hep B Vaccination; Thyroid Dysfunction Alert Following ICM
A second booster dose for some COVID-19 vaccines is authorized; Sotrovimab has its use limited due to the BA.2 Omicron subvariant; An investigational oral antiviral gains Fast Track designation; PreHe...
1 Apr 202211min
